France's Valbiotis announces positive top-line data for Valedia IIA clinical study

recently,(http:// of Valbiotis, France,published positive top-line data for clinical studies in Valedia (active ingredient: TOTUM-63) IIAthe study, conducted in people with prediabetes, assessed Valedia's efficacy and safety relative to placeboresults showed that in this group, Valedia significantly lowered fasting and post-meal blood sugar levels compared to placebos, two major risk factors for type 2 diabetes and the primary and secondary endpoints of the studyValedia also significantly reduced weight and waist circumference compared to placebosbased on these results, Valedia became the first clinically provenproduct(http://for patients with prediabetes to reduce multiple risk factors for type 2 diabetesAccording to the study, Valbiotis has initiated the last two Phase IIb clinical studies (REVERSE-IT and PREVENT-IT) at the same timeSince moderate fasting hyperglycemia is a major risk factor for type 2 diabetes in prediabetes, the two studies focused on fasting blood sugar levels, and the data will be used to supportclaims ofHealth(http:// to reduce the risk of type 2 diabetes in Valedia, Europe and North AmericaThis regulatory process does not require a Phase III study As mentioned earlier, Valedia's commercialization is scheduled for 2021 　　About Valedia Valedia is the first product to be clinically proven for patients with prediabetes to reduce the risk of type 2 diabetes Valedia's active drug (http:// component is TOTUM-63, a unique combination of five plant extracts (http:// , with a total of 63 bioactive molecules and synergies of five key metabolic organs (liver, pancreas, intestines, muscles, adipose tissue) targeting the physiological pathology of type 2 diabetes 　　In clinical studies, TOTUM-63 has demonstrated perfect tolerance and safety as a natural plant product